Epidemiological studies in non-surgical patients have shown that the use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have an overall effect of 18% risk reduction in new-onset AF across the trials, and 43% risk reduction in patients with heart failure [13]. Here, ACE is linked to atrial fibrillation.